Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-20182004-2018년 영국에서 심부전 진단 시 나트륨 이뇨 펩티드 수준 및 입원 및 사망 위험Article Published on 2022-04-012022-09-11 Journal: Heart (British Cardiac Society) [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] 95% CI age all-cause mortality rates association baseline clinical cohort study competing COVID-19 death diagnosed Diagnosis diagnostic England greater guideline Healthcare system Healthcare systems heart heart failure Heart failure. hospitalisation hospitalised IMPROVE IQR mandatory median time men moderate Mortality mortality rate mortality rates Natriuretic NT-proBNP participant Patient peptide Practice pressure Prevent primary care Referral Research risk secondary care survival Treatment while [DOI] 10.1136/heartjnl-2021-319196 PMC 바로가기 [Article Type] Article
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials코로나바이러스 질병 2019 치료를 위한 이버멕틴: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-03-232022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, [키워드] 95% confidence interval Adult patients adverse event adverse events AEs all-cause mortality all-cause mortality rate all-cause mortality rates benefit Bia confidence interval Control control group control groups Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 disease severity did not reduce Effect evaluated Evidence Hospital stay inverse Ivermectin LOS main analyses mean difference meta-analyses Meta-analysis meta-analysis Mild moderate Mortality mortality rates mortality. outcome outcomes Patient patients with COVID-19 performed Placebo Primary outcomes random effect Randomized controlled trial Randomized controlled trials RCT RCTs reduced Relative risk review risk risk of bia RoB SAE SAEs SARS-CoV-2 searched secondary Secondary outcomes severe AE severe AEs severity of COVID-19 Standard of care subgroups treat viral clearance [DOI] 10.1093/cid/ciab591 PMC 바로가기 [Article Type] Meta-Analysis
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trialDEXamethasone(CoDEX)으로 치료된 COVID-19 관련 ARDS: 무작위 시험에 대한 연구 설계 및 근거Original Article Published on 2020-01-012022-08-13 Journal: Revista Brasileira de Terapia Intensiva [Category] 임상, [키워드] 350 patient 350 patients 48 hour 48 hours 6-level ordinal scale acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Adrenal cortex hormones Adult patients all-cause mortality rate all-cause mortality rates assessment Berlin criteria caused clinical status clinical trial Control control group Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 - COVID-19 Corticosteroid Corticosteroides Corticosteroids COVID-19 COVID-19-associated ARDS Cuidados críticos days alive defined develop Dexametasona Dexamethasone dexamethasone 10mg IV dexamethasone 20mg intravenous early-onset Effectiveness Eligible patients evaluate evaluated failure followed by group hospitalized patient hospitalized patients Infection intensive care intervention group intravenous Invasive mechanical ventilation less mechanical ventilation mechanical ventilation duration moderate mortality rates multicenter Non-COVID-19 non-COVID-19 acute respiratory distress syndrome objective occur once daily Open-label Ordinal Scale outcome pandemic Patient patients with moderate Pneumonia Pragmatic Primary outcome randomization Randomized randomized trial Randomly receive respiratory respiratory compromise respiratory distress Respiratory distress syndrome Respiratory distress syndrome, adult Síndrome do desconforto respiratório do adulto SARS-CoV-2 SARS-COV-2 infection score secondary Secondary outcomes severe acute respiratory syndrome Coronavirus Spread standard treatment stratified Study design syndrome treated Trial unit discharge ventilator-free day Ventilator-free days Viral Viral pneumonia [DOI] 10.5935/0103-507X.20200063 PMC 바로가기 [Article Type] Original Article